Thomas E Stinchcombe

UNCCH, School of Medicine, Medicine

• Home
• Expert Overview
• Profile
• Publications
• Grants
• Patents
• Similar Experts
• Journals
• Trends
• Institutional Network
• Coauthor Network
• Research Network

Thomas E Stinchcombe

• Organizations
  University of North Carolina at Chapel Hill
  
  School of Medicine
  
  Medicine
  
  

Help us refine your profile

This is a list of publications by this researcher, listed chronologically starting with the most recent first. New publications appear in this list weekly. The source of publications and 'cited by' data for this application is Scopus.

  Select All    |   Export

• 1.

  2013

  Thomas E. Stinchcombe; Joanna Roder; Amy H. Peterman; Julia Grigorieva; Carrie B. Lee; Dominic T. Moore; Mark A. Socinski

  A retrospective analysis of veristrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer

  Journal of Thoracic Oncology. 2013;8(4):443-451.
  0

• 2.

  2013

  Patrick J. Roberts; Thomas E. Stinchcombe

  KRAS mutation: Should we test for it, and does it matter

  Journal of Clinical Oncology. 2013;31(8):1112-1121.
  0

• 3.

  2013

  Juneko E. Grilley-Olson; D. Neil Hayes; Dominic T. Moore; Kevin O. Leslie; Matthew D. Wilkerson; Bahjat F. Qaqish; Michele C. Hayward; Christopher R. Cabanski; Xiaoying Yin; Mark A. Socinski; et al.

  Validation of interobserver agreement in lung cancer assessment: Hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: The 2004 world health organization classification and therapeutically relevant subsets

  Archives of Pathology and Laboratory Medicine. 2013;137(1):32-40.
  0

• 4.

  2012

  Mark A. Socinski; Thomas E. Stinchcombe; Dominic T. Moore; Scott N. Gettinger; Roy H. Decker; W. Jeffrey Petty; A. William Blackstock; Garry Schwartz; Scott Lankford; Amir Khandani; et al.

  Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: Results of a phase I/II trial

  Journal of Clinical Oncology. 2012;30(32):3953-3959.
  1

• 5.

  2012

  E. Claire Dees; Roger B. Cohen; Margaret Von Mehren; Thomas E. Stinchcombe; Hua Liu; Karthik Venkatakrishnan; Mark Manfredi; Howard Fingert; Howard A. Burris III; Jeffrey R. Infante

  Phase I study of Aurora a kinase inhibitor MLN8237 in advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations

  Clinical Cancer Research. 2012;18(17):4775-4784.
  0

• 6.

  2012

  Pasi A. Jänne; Xiaofei Wang; Mark A. Socinski; Jeffrey Crawford; Thomas E. Stinchcombe; Lin Gu; Marzia Capelletti; Martin J. Edelman; Miguel A. Villalona-Calero; Robert Kratzke; et al.

  Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial

  Journal of Clinical Oncology. 2012;30(17):2063-2069.
  18

• 7.

  2012

  Thomas E Stinchcombe; David Cella

  Does maintenance pemetrexed maintain quality of life?

  The Lancet Oncology. 2012;13(3):224-225.
  0

• 8.

  2012

  Thomas E. Stinchcombe; Jeffrey A. Bogart

  Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer

  Oncologist. 2012;17(5):682-693.
  0

• 9.

  2012

  Jared Weiss; Thomas E Stinchcombe

  Treatment of elderly patients with stage IV non-small-cell lung cancer

  Expert Review of Anticancer Therapy. 2012;12(1):111-120.
  0

• 10.

  2011

  Joseph K. Salama; Thomas E. Stinchcombe; Lin Gu; Xiaofei Wang; Karen Morano; Jeffrey A. Bogart; Jeffrey C. Crawford; Mark A. Socinski; A. William Blackstock; Everett E. Vokes

  Pulmonary toxicity in stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: A secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105

  International Journal of Radiation Oncology Biology Physics. 2011;81(4):e269-e274.
  4

• 11.

  2011

  Hanna K. Sanoff; Janine M. Davies; Christine Walko; William Irvin; Larry Buie; Kimberly Keller; Anastasia Ivanova; Wing-Keung Chiu; Bert H. O'Neil; Thomas E. Stinchcombe; et al.

  A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors

  Investigational New Drugs. 2011;29(5):978-983.
  2

• 12.

  2011

  Thomas E. Stinchcombe; Amy H. Peterman; Carrie B. Lee; Dominic T. Moore; Jennifer L. Beaumont; Daniel S. Bradford; Kamal Bakri; Mark Taylor; Jeffrey M. Crane; Garry Schwartz; et al.

  A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer

  Journal of Thoracic Oncology. 2011;6(9):1569-1577.
  4

• 13.

  2011

  Ramaswamy Govindan; Jeffrey Bogart; Thomas Stinchcombe; Xiaofei Wang; Lydia Hodgson; Robert Kratzke; Jennifer Garst; Timothy Brotherton; Everett E. Vokes

  Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and leukemia group B trial 30407

  Journal of Clinical Oncology. 2011;29(23):3120-3125.
  23

• 14.

  2011

  Thomas E. Stinchcombe; Jeffery Bogart; Nirmal K. Veeramachaneni; Robert Kratzke; Ramaswamy Govindan

  Annual review of advances in non-small cell lung cancer research: A report for the year 2010

  Journal of Thoracic Oncology. 2011;6(8):1443-1450.
  2

• 15.

  2011

  Thomas E Stinchcombe; Channing J Der

  Are all KRAS mutations created equal?

  The Lancet Oncology. 2011;12(8):717-718.
  4

• 16.

  2011

  Janine M. Davies; Nirav S. Dhruva; Christine M. Walko; Mark A. Socinski; Stephen Bernard; D. Neil Hayes; William Y. Kim; Anastasia Ivanova; Kimberly Keller; Layla R. Hilbun; et al.

  A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients

  Lung Cancer. 2011;71(2):151-155.
  3

• 17.

  2011

  Hanna K. Sanoff; Janine Davies; Christine Walko; Larry Buie; Wing-Keung Chiu; Anastasia Ivanova; Bert O'Neil; Thomas E. Stinchcombe; Kimberly Keller; E. Claire Dees

  Phase i trial of vinflunine and pemetrexed in refractory solid tumors

  Investigational New Drugs. 2011;29(1):131-136.
  1

• 18.

  2011

  Thomas E. Stinchcombe; Maria Q. Baggstrom; Neeta Somaiah; George R. Simon; Ramaswamy Govindan

  Summary of presentations from the 46th annual meeting of the american society of clinical oncology: Focus on non-small cell lung cancer (2010)

  Journal of Thoracic Oncology. 2011;6(1):227-232.
  3

• 19.

  2011

  Thomas E. Stinchcombe; Mark A. Socinski

  Maintenance therapy in advanced non-small cell lung cancer: Current status and future implications

  Journal of Thoracic Oncology. 2011;6(1):174-182.
  13

• 20.

  2010

  Mark A. Socinski; Robert N. Raju; Thomas Stinchcombe; Darren M. Kocs; Linda S. Couch; David Barrera; Steven R. Rousey; Janak K. Choksi; Robert Jotte; Debra A. Patt; et al.

  Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer

  Journal of Thoracic Oncology. 2010;5(12):1963-1969.
  9

• 21.

  2010

  Patrick J. Roberts; Thomas E. Stinchcombe; Channing J. Der; Mark A. Socinski

  Personalized medicine in non-small-cell lung cancer: Is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

  Journal of Clinical Oncology. 2010;28(31):4769-4777.
  73

• 22.

  2010

  Thomas E. Stinchcombe; Mark A. Socinski

  Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy

  Nature Reviews Clinical Oncology. 2010;7(8):426-428.
  3

• 23.

  2010

  Thomas E. Stinchcombe; Jeffrey Bogart; Dennis A. Wigle; Ramaswamy Govindan

  Annual review of advances in lung cancer clinical research: A report for the year 2009

  Journal of Thoracic Oncology. 2010;5(7):935-939.
  8

• 24.

  2010

  T.E. Stinchcombe; R. Govindan

  One more fallen star-ZODIAC and its implications

  The Lancet Oncology. 2010;11(7):604-605.
  1

• 25.

  2010

  Thomas E Stinchcombe; Suresh S Ramalingam

  Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?

  The Lancet Oncology. 2010;11(6):500-501.
  0

• 26.

  2010

  Thomas E. Stinchcombe; Juneko E. Grilley-Olson; Mark A. Socinski

  If histology matters...

  Journal of Clinical Oncology. 2010;28(11):1810-1812.
  5

• 27.

  2010

  Thomas E. Stinchcombe; Elizabeth M. Gore

  Limited-stage small cell lung cancer: Current chemoradiotherapy treatment paradigms

  Oncologist. 2010;15(2):187-195.
  9

• 28.

  2010

  Thomas E Stinchcombe

  Anti-angiogenesis therapy in the treatment of non-small cell lung cancer: The role of monoclonal antibodies and multitargeted tyrosine kinase inhibitors

  European journal of Clinical and Medical Oncology. 2010;2(1).
  0

• 29.

  2010

  Thomas E. Stinchcombe; Daniel S. Bradford; Thomas A. Hensing; Renato V. LaRocca; Mansoor Saleh; Tracey Evans; Kamal Bakri; Mark A. Socinski

  A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer

  Cancer Investigation. 2010;28(2):208-215.
  3

• 30.

  2009

  Boone Goodgame; Thomas E. Stinchcombe; George Simon; Antoinette Wozniak; Ramaswamy Govindan

  Recent advances in lung cancer: Summary of presentations from the 45th annual meeting of the American society of clinical oncology (2009)

  Journal of Thoracic Oncology. 2009;4(10):1293-1300.
  2

• 31.

  2009

  Thomas E. Stinchcombe; Lydia Hodgson; James E. Herndon II; Michael J. Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey B. Niell; James N. Atkins; Wallace Akerley; Mark R. Green; et al.

  Treatment outcomes of different prognostic groups of patients on Cancer and Leukemia Group B trial 39801: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer

  Journal of Thoracic Oncology. 2009;4(9):1117-1125.
  15

• 32.

  2009

  Thomas E. Stinchcombe; Mark A. Socinski

  Current treatments for advanced stage non-small cell lung cancer

  Proceedings of the American Thoracic Society. 2009;6(2):233-241.
  55

• 33.

  2009

  Thomas E. Stinchcombe; Mark A. Socinski

  Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy

  Journal of Thoracic Oncology. 2009;4(2):243-250.
  22

• 34.

  2009

  Carrie B. Lee; Thomas E. Stinchcombe; Dominic T. Moore; David E. Morris; D Neil Hayes; Jan Halle; Julian G. Rosenman; M Patricia Rivera; Mark A. Socinski

  Late complications of high-dose (≥66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer

  Journal of Thoracic Oncology. 2009;4(1):74-79.
  10

• 35.

  2009

  Thomas E Stinchcombe; Howard L West

  Maintenance therapy in non-small-cell lung cancer

  The Lancet. 2009;374(9699):1398-1400.
  9

• 36.

  2009

  Benjamin E. Haithcock; Thomas E. Stinchcombe; Mark A. Socinski

  Treatment of surgically resectable non-small-cell lung cancer in elderly patients

  Clinical Lung Cancer. 2009;10(6):405-409.
  2

• 37.

  2008

  Thomas E. Stinchcombe; Carrie B. Lee; Dominic T. Moore; M Patricia Rivera; Jan Halle; Steven Limentani; Julian G. Rosenman; Mark A. Socinski

  Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer

  Journal of Thoracic Oncology. 2008;3(11):1279-1285.
  7

• 38.

  2008

  Thomas E. Stinchcombe; Ann M. Mauer; Lydia D. Hodgson; James E. Herndon; Thomas J. Lynch; Mark R. Green; Everett E. Vokes

  Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and leukemia group B trial 9430

  Journal of Thoracic Oncology. 2008;3(11):1301-1307.
  0

• 39.

  2008

  Thomas E. Stinchcombe; Mark A. Socinski

  Gefitinib in advanced non-small cell lung cancer: Does it deserve a second chance?

  Oncologist. 2008;13(9):933-944.
  11

• 40.

  2008

  T.E. Stinchcombe; D.E. Morris; C.B. Lee

  Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIa and stage IIIb, non-small cell lung cancer (Journal of Thoracic Oncology (2008) 3, (250-257))

  Journal of Thoracic Oncology. 2008;3(6):687.
  0

• 41.

  2008

  Thomas E. Stinchcombe; Mark A. Socinski; Carrie B. Lee; D. Neil Hayes; Dominic T. Moore; Richard M. Goldberg; E. Claire Dees

  Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies

  Journal of Thoracic Oncology. 2008;3(5):521-526.
  9

• 42.

  2008

  Thomas E. Stinchcombe; David E. Morris; Carrie B. Lee; Dominic T. Moore; D. Neil Hayes; Jan S. Halle; M. Patricia Rivera; Julian G. Rosenman; Mark A. Socinski

  Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer

  Journal of Thoracic Oncology. 2008;3(3):250-257.
  34

• 43.

  2008

  Thomas E. Stinchcombe; Daniel B. Fried; Maria Q. Baggstrom; Thomas A. Hensing; Mark A. Socinski

  Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: A meta-analysis [2]

  Journal of Thoracic Oncology. 2008;3(3):320-322.
  1

• 44.

  2008

  Thomas E. Stinchcombe; Harry D. Harper; Thomas A. Hensing; Dominic T. Moore; Jeffery M. Crane; James N. Atkins; Ellen M. Willard; Frank C. Detterbeck; Mark A. Socinski

  The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer

  Journal of Thoracic Oncology. 2008;3(2):145-151.
  6

• 45.

  2008

  Thomas E. Stinchcombe; Mark A. Socinski

  Considerations for second-line therapy of non-small cell lung cancer

  Oncologist. 2008;13(SUPPL. 1):28-36.
  52

• 46.

  2007

  Mark A. Socinski; Thomas E. Stinchcombe

  Duration of first-line chemotherapy in advanced non-small-cell lung cancer: Less is more in the era of effective subsequent therapies

  Journal of Clinical Oncology. 2007;25(33):5155-5157.
  23

• 47.

  2007

  Thomas E. Stinchcombe; Mark A. Socinski; Christine M. Walko; Bert H. O'Neil; Frances A. Collichio; Anastasia Ivanova; Hua Mu; Michael J. Hawkins; Richard M. Goldberg; Celeste Lindley; et al.

  Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

  Cancer Chemotherapy and Pharmacology. 2007;60(5):759-766.
  36

• 48.

  2007

  Thomas E. Stinchcombe; Frank C. Detterbeck; Li Lin; M. Patricia Rivera; Mark A. Socinski

  Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer

  Journal of Thoracic Oncology. 2007;2(9):819-826.
  5

• 49.

  2007

  Maria Q. Baggstrom; Thomas E. Stinchcombe; Daniel B. Fried; Charles Poole; Thomas A. Hensing; Mark A. Socinski

  Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: A meta-analysis

  Journal of Thoracic Oncology. 2007;2(9):845-853.
  51

• 50.

  2007

  Bert H. O'Neil; Robert Allen; David R. Spigel; Thomas E. Stinchcombe; Dominic T. Moore; Jordan D. Berlin; Richard M. Goldberg

  High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history

  Journal of Clinical Oncology. 2007;25(24):3644-3648.
  88

• 51.

  2007

  Thomas E. Stinchcombe

  Nanoparticle albumin-bound paclitaxel: A novel Cremphor-EL®-free formulation of paclitaxel

  Nanomedicine. 2007;2(4):415-423.
  39

• 52.

  2007

  T.E. Stinchcombe; M.A. Socinski

  Bevacizumab in the treatment of non-small-cell lung cancer

  Oncogene. 2007;26(25):3691-3698.
  18

• 53.

  2007

  Thomas E. Stinchcombe; Ruth Walters; Amir H. Khandani; Mark A. Socinksi

  Radiation-induced sarcoma after high-dose thoracic radiation therapy in non-small-cell lung cancer

  Journal of Clinical Oncology. 2007;25(12):1621-1623.
  5

• 54.

  2007

  Thomas E. Stinchcombe; Mark A. Socinski

  The role of induction therapy for resectable non-small cell lung cancer

  Drugs. 2007;67(3):321-332.
  2

• 55.

  2007

  Thomas E. Stinchcombe

  Targeted therapy of advanced non-small cell lung cancer: The role of bevacizumab

  Biologics: Targets and Therapy. 2007;1(3):185-194.
  0

• 56.

  2006

  Carrie B. Lee; Thomas E. Stinchcombe; Julian G. Rosenman; Mark A. Socinski

  Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: Evolving role of dose-escalated conformal (3-dimensional) radiation therapy

  Clinical Lung Cancer. 2006;8(3):195-202.
  18

• 57.

  2006

  Thomas E. Stinchcombe; Mark A. Socinski; Lisa M. Gangarosa; Amir H. Khandani

  Lung cancer presenting with a solitary colon metastasis detected on positron emission tomography scan

  Journal of Clinical Oncology. 2006;24(30):4939-4940.
  8

• 58.

  2006

  Thomas E. Stinchcombe; Petra Bůžková; Janak Choksi; Mark Taylor; Kamal Bakri; Heidi Gillenwater; Maureen Tynan; Andrea Mears; Paul E. Jones; Mark A. Socinski

  A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer

  Lung Cancer. 2006;52(3):305-311.
  8

• 59.

  2006

  Thomas E. Stinchcombe; Carrie B. Lee; Mark A. Socinski

  Current approaches to advanced-stage non-small-cell lung cancer: First-line therapy in patients with a good functional status

  Clinical Lung Cancer. 2006;7(SUPPL. 4):S111-S117.
  17

• 60.

  2006

  Thomas E. Stinchcombe; David E. Morris; Dominic T. Moore; John H. Bechtel; Jan S. Halle; Andrea Mears; Katherine Deschesne; Julian G. Rosenman; Mark A. Socinski

  Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy

  Lung Cancer. 2006;52(1):67-74.
  11

• 61.

  2006

  Thomas E. Stinchcombe; Jaeun Choi; Michael J. Schell; Andrea Mears; Paul E. Jones; Robert V. Nachtsheim; Mark A. Socinski

  Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status

  Lung Cancer. 2006;51(2):237-243.
  9

• 62.

  2006

  Mark A. Socinski; Thomas E. Stinchcombe; D. Neil Hayes; David E. Morris

  The emergence of a unique population in non-small cell lung cancer: Systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy

  Seminars in Oncology. 2006;33(SUPPL. 1):S32-S38.
  1

• 63.

  2006

  Thomas E. Stinchcombe; Daniel Fried; David E. Morris; Mark A. Socinski

  Combined modality therapy for stage III non-small cell lung cancer

  Oncologist. 2006;11(7):809-823.
  18

• 64.

  2006

  Thomas E. Stinchcombe; Daniel Fried; David E. Morris; Mark A. Socinski

  Erratum: Combined modality therapy for stage III non-small cell lung cancer (Oncologist (2006), 11 (809-823))

  Oncologist. 2006;11(8):958.
  0

• 65.

  2005

  Mark A. Socinski; Thomas E. Stinchcombe; D. Neil Hayes

  The evolving role of pemetrexed (Alimta) in lung cancer

  Seminars in Oncology. 2005;32(SUPPL. 2):S16-S22.
  8

• 66.

  2005

  Heidi H. Gillenwater; Thomas E. Stinchcombe; Bahjat F. Qaqish; Maureen Tyann; Thomas A. Hensing; Mark A. Socinski

  A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer

  Lung Cancer. 2005;47(3):413-419.
  4

• 67.

  2005

  Johann Brandes; Julie Brahmer; Giuseppe Giaccone; Fabrice Barlesi; Thomas E. Stinchcombe; D. Neil Hayes; Mark A. Socinski

  Perspectives on salvage therapy for non-small-cell lung cancer: Commentary

  ONCOLOGY. 2005;19(8):995-996+999-1000+1003-1004+1006.
  0

• 68.

  2004

  Thomas E. Stinchcombe; Mark A. Socinski

  Drug development in patients with advanced non-small cell lung cancer and poor performance status

  Seminars in Oncology. 2004;31(SUPPL. 11):21-26.
  4

• 69.

  2004

  Leslie Fischer; Chrysa Mahoney; A. Robert Jeffcoat; Matthew A. Koch; Brian F. Thomas; John L. Valentine; Thomas Stinchcombe; Jarol Boan; James A. Crowell; Steven H. Zeisel

  Clinical characteristics and pharmacokinetics of purified soy isoflavones: Multiple-dose administration to men with prostate neoplasia

  Nutrition and Cancer. 2004;48(2):160-170.
  46

• 70.

  2002

  Robert Z. Orlowski; Thomas E. Stinchcombe; Beverly S. Mitchell; Thomas C. Shea; Albert S. Baldwin; Stephanie Stahl; Julian Adams; Dixie-Lee Esseltine; Peter J. Elliott; Christine S. Pien; et al.

  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

  Journal of Clinical Oncology. 2002;20(22):4420-4427.
  492

• 71.

  2001

  Harold R. Roberts; Thomas E. Stinchcombe; Don A. Gabriel

  The dysfibrinogenaemias

  British Journal of Haematology. 2001;114(2):249-257.
  41

• 72.

  1999

  Paul A. Godley; Thomas E. Stinchcombe

  Renal cell carcinoma

  Current Opinion in Oncology. 1999;11(3):213-217.
  24